We confirmed that the mutant versions of p53 were essential to maintain the oncogenic phenotype, while reduction of p53 expression by specific shRNA strongly reduced proliferation of the gliomas assayed, with a clear correlation to the reduction of CD133+ cells [45]. This evidence concerns the gene TP53 and glioma.